NAGE - NASDAQ
NB
Niagen Bioscience Inc
NAGE·NASDAQ
$3.50
-1.1%HealthcareBiotechnology
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
At a Glance
Live SnapshotMarket Cap$278.76M
EPS0.2200
P/E Ratio15.91
Earnings Date08/05/2026
nage
Common Stock
Last Annual Value
79.00K
3-Year CAGR
2%
5-Year CAGR
5%
10-Year CAGR
8%
NB
Niagen Bioscience Inc Competitors Analysis of Common Stock
NAGE · NASDAQ
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Niagen Bioscience Inc NASDAQ:NAGE | 79.00K | 1.7% | 3.0% | 7.7% | |
 Prothena Corporation plc NASDAQ:PRTA | 538.00K | 0.1% | 2.9% | 4.5% | |
 Akebia Therapeutics, Inc. NASDAQ:AKBA | 2.00K | 0.0% | 14.9% | N/A | |
 Ventyx Biosciences, Inc. NASDAQ:VTYX | 7.00K | 5.3% | 7.0% | N/A | |
 Keros Therapeutics, Inc. NASDAQ:KROS | 4.00K | 10.1% | 14.9% | N/A | |
 REGENXBIO Inc. NASDAQ:RGNX | 5.00K | 7.7% | 4.6% | 5.2% | |
 Olema Pharmaceuticals, Inc. NASDAQ:OLMA | 8.00K | 26.0% | 21.7% | N/A | |
 Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | 7.00K | 11.9% | 7.0% | 13.3% | |
 KalVista Pharmaceuticals, Inc. NASDAQ:KALV | 51.00K | 14.5% | 16.3% | 32.8% | |
 Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | 18.00K | 1.9% | -36.3% | -15.8% | |
 Zevra Therapeutics, Inc. NASDAQ:ZVRA | 6.00K | 14.5% | 8.4% | 19.6% |
NB
Niagen Bioscience Inc Fair Value Envelope
NAGE · NASDAQ
Related Guides
Continue your NAGE research with focused valuation guides.
Research Paths
1
Snapshot
Start with context, operating signals, and key market metrics.
2
Value Model
Stress test fair value across bear, base, and bull assumptions.
3
Statements
Validate revenue quality, margins, and balance sheet durability.
4
Earnings Call
Read management commentary and compare it with reported outcomes.
5
Dividends
Check payout sustainability and long-term distribution behavior.
6
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.